Larimar Therapeutics (NASDAQ:LRMR) Given New $15.00 Price Target at Wedbush
Larimar Therapeutics (NASDAQ:LRMR – Free Report) had its target price decreased by Wedbush from $17.00 to $15.00 in a research report report published on Tuesday,Benzinga reports. Wedbush currently has an outperform rating on the stock. LRMR has been the topic of a number of other research reports. Guggenheim reissued a “buy” rating and set a […]
Larimar Therapeutics (NASDAQ:LRMR – Free Report) had its target price decreased by Wedbush from $17.00 to $15.00 in a research report report published on Tuesday,Benzinga reports. Wedbush currently has an outperform rating on the stock. LRMR has been the topic of a number of other research reports. Guggenheim reissued a “buy” rating and set a […]
